Patents by Inventor Maciej Wieczorek

Maciej Wieczorek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160039794
    Abstract: A compound represented by the general Formula (I), wherein hydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; R1 represents —X-Q-P, wherein X is absent or represents —CH2—, —C(O)—, or —C(O)NH—(CH2)k—, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight- or branched-chain C1-C3 alkyl, —(CH2)l—NR2R3, or —(CH2)m—C(O)—NR2R3, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent; and R2 and R3 independently represent C1 or C2 alkyl, or R2 and R3 together with nitrogen atom to which they are both attached form a 6-membered saturated heterocyclic ring, wherein one of carbon atoms can be replaced with oxygen, —NH—or —N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases.
    Type: Application
    Filed: March 7, 2014
    Publication date: February 11, 2016
    Applicant: CELON PHARMA S.A.
    Inventors: Daria ZDZALIK, Joanna LIPNER, Maciej WIECZOREK, Karolina DZWONEK, Abdellah YAMANI, Krzysztof DUBIEL, Monika LAMPARSKA-PRZYBYSZ, Paulina GRYGIELEWICZ, Aleksandra STANCZAK
  • Publication number: 20090264510
    Abstract: The present invention relates to the application of double-helical oligonucleotides (siRNA) interfering with the mRNA of gene involved in carcinogenesis, particularly the Wnt1, Wnt2 or Her3 genes. Such oligonucleotides may be modified chemically, used in conjunction with viral and non-viral vectors such as lipid complexes. Such oligonucleotides exhibit unusual anti-proliferative properties against tumour cells and may be used in anti-tumour treatment.
    Type: Application
    Filed: July 30, 2008
    Publication date: October 22, 2009
    Inventors: Maciej Wieczorek, Joanna Wietrzyk, Anna Nasulewicz, Katarzyna Szczaurska, Jan Piotr Guzenda, Monika Lamparska-Przyhysz
  • Patent number: 7057041
    Abstract: The invention relates to a process for the preparation of zaleplon (N-[3(3-cyanopyrazolo[1,5-a]pyrim-idin-7-yl)phenyl]-N-ethyl-accramide) in the reaction of 3-dimethylamino-1-(3-N-ethyl-N-acetylamirnophenyl)-2-propen-1-one with 3-aminopyrazole-4-carbonitrile, which comprises carrying out said reaction in an aqueous solution of formic acid at formic acid concentrations in the range of 20–80% (w/w). Zaleplon is useful as an anxiolytic, a sedactive and a skeletal muscle relaxant.
    Type: Grant
    Filed: May 12, 2003
    Date of Patent: June 6, 2006
    Inventors: Monika Korycinska, Tomasz Stawinski, Maciej Wieczorek
  • Publication number: 20050277582
    Abstract: Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, .alpha.-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.
    Type: Application
    Filed: July 29, 2005
    Publication date: December 15, 2005
    Inventors: Torrance Nett, Leonard Glode, Maciej Wieczorek, Paul Jarosz
  • Publication number: 20050234237
    Abstract: The invention relates to a process for the preparation of zaleplon (N-[3(3-cyanopyrazolo[1,5-a]pyrim-idin-7-yl)phenyl]-N-ethyl-accramide) in the reaction of 3-dimethylamino-1-(3-N-cthyl-N-acetylamirnophenyl)-2-propen-1-one with 3-aminopyrazole-4-carboniitrile, which comprises carrying out said reaction in an aqueous solution of formic acid at formic acid concentrations in the range of 20-80% (w/w). Zaleplon is useful as an anxiolytic, a sedactive and a skeletal muscle relaxant.
    Type: Application
    Filed: May 12, 2003
    Publication date: October 20, 2005
    Inventors: Monika Korycinska, Tomasz Stawinski, Maciej Wieczorek
  • Patent number: 6924268
    Abstract: Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, ?-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.
    Type: Grant
    Filed: January 21, 2002
    Date of Patent: August 2, 2005
    Assignee: Colorado State University Research Foundation
    Inventors: Torrance M. Nett, Leonard Michael Glode, Maciej Wieczorek, Paul J. Jarosz
  • Publication number: 20020165126
    Abstract: Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, &agr;-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.
    Type: Application
    Filed: January 21, 2002
    Publication date: November 7, 2002
    Applicant: Colorado State University Research Foundation
    Inventors: Torrance M. Nett, Leonard Michael Glode, Maciej Wieczorek, Paul J. Jarosz
  • Patent number: 6326467
    Abstract: Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, &agr;-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: December 4, 2001
    Assignee: Colorado State University Research Foundation
    Inventors: Torrance M. Nett, Leonard Michael Glode, Maciej Wieczorek, Paul J. Jarosz
  • Patent number: D737425
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: August 25, 2015
    Assignee: Celon Pharma S.A.
    Inventor: Maciej Wieczorek
  • Patent number: D746378
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: December 29, 2015
    Assignee: Celon Pharma S.A.
    Inventors: Bogdan Szczepan Manowski, Maciej Wieczorek